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IDS is the end result of a prolonged dynamic war of
attrition between virus and host, marked by prodi-
gious rates of viral replication opposed by host immune re-
sponses and remarkable rates of T cell regeneration (1, 2).
Understanding the ultimate failure of the host immune re-
sponses to control HIV replication remains one of the cen-
tral challenges of HIV research. This commentary will focus
on efforts to understand why the host cytotoxic T lym-
phocyte (CTL) response, normally a potent effector re-
sponse against viral infections, is unable to contain AIDS
virus replication.
Most HIV-infected people develop a strong and broadly
directed CTL response against HIV (3). This CTL response,
 
which is mediated largely by classical CD8
 
1
 
, MHC class
I–restricted lymphocytes, can often be detected without in
vitro stimulation, indicating a high frequency of circulating
activated effector cells (4). Direct evidence for a high fre-
quency of HIV-specific CTL (up to 1% of all T cells) has
been provided by molecular analysis of the frequency of T
cell receptors specific for a single CTL epitope (5) and by
flow cytometric analysis of lymphocytes from HIV-infected
subjects using fluorescently labeled HLA-A2 molecules
complexed with a HIV peptide (6). In addition to their rel-
atively high frequency, HIV-specific CTL typically recog-
nize multiple epitopes in a single subject, generally in con-
served regions of the virus (4, 7). Definitive evidence for an
in vivo effect of this vigorous in vitro response has been
difficult to establish, but the finding that the onset of CTL
responses during primary infection with HIV-1 coincides with
the control of viral replication, suggests that HIV-specific
CTL are likely to suppress viral replication in vivo (8). Yet,
viral replication continues to occur in HIV-infected indi-
viduals despite CTL responses and replication ultimately
increases as individuals progress to AIDS, often in conjunc-
tion with a decline in CTL activity (9).
A variety of mechanisms have been proposed to account
for the failure of CTL responses to effectively control HIV
(Table 1) (10, 11), many of which have been previously
described for other viral pathogens. Sequence variation has
been the leading contender to account for the escape of
HIV from CTL control, yet unequivocal evidence to doc-
ument this hypothesis has proved elusive. HIV replication
occurs at a rapid rate in vivo, leading to the production of
 
10
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 virions per day (1, 2). Coupled with the error-prone
nature of reverse transcriptase, this rapid rate of replication
results in a diverse population of viruses that are likely to
contain a mutation within any given CTL epitope. This viral
diversity rapidly results in evolution of viruses resistant to
antiretroviral agents (1) and since single–amino acid changes
can abort recognition by HIV-specific CTL (12), it was
logical to propose that emergence of HIV strains unrecog-
nized by CTL might be a dominant mechanism of escape.
Although an early report demonstrated that evolution of
HIV variants unrecognized by CTL could occur (13), it has
been unclear whether these mutants emerged as the result
of random variation or as a direct result of selection pres-
sure by CTL. Other reports did not observe the emergence of
escape mutations in CTL epitopes in either HIV-infected
people or simian immunodeficiency virus (SIV) infected mon-
keys (14, 15), and a comprehensive analysis of the fre-
quency of escape mutations in two subjects with a poly-
clonal CTL response has revealed dominant unrecognized
sequences in only 3 of 16 epitopes examined (Johnson,
R.P., S. Kalams, B.D. Walker, manuscript in preparation).
However, there are now several examples that provide
compelling evidence that CTL responses may select for un-
recognized variant viruses in vivo (16, 17, 18), especially in
instances when the dominant CTL response is directed
against a single epitope. Taken together, these observations
suggest that evolution of escape mutations may contribute
to the ability of HIV to escape CTL surveillance, but they
do not suggest that mutations in CTL epitopes are the dom-
inant mechanism of immune escape.
Another strategy commonly employed by viral patho-
gens to evade CTL responses is interference with MHC
class I–restricted processing of viral proteins. These mecha-
nisms include downregulation of MHC class I molecules
(19), dislocation of class I molecules from the endoplasm
reticulum (20), blocking the transport of processed peptides
into the endoplasmic reticulum (21), and selective inhibi-
tion of processing of specific viral proteins (22). Several re-
ports have documented partial downregulation of MHC
class I molecules in HIV-infected cells, a function ascribed to
the viral proteins Tat or Nef (23, 24). Whether this down-
regulation was sufficient to affect recognition by HIV-spe-
cific CTL has been difficult to assess, because most investi-
gators have not analyzed recognition of naturally infected
T cells, relying instead on the more convenient system of
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employing EBV-transformed B cell lines infected with re-
combinant vaccinia-expressing HIV proteins. Recent data
analyzing recognition by HIV-specific CTL clones of trans-
formed cell lines infected with laboratory-adapted HIV strains
(which may be defective in viral proteins such as Nef) sug-
gested that partial downregulation of MHC class I mole-
cules does not appear to affect recognition by HIV-specific
CTL (25), but these results need to be validated using pri-
mary HIV strains and primary T cells.
Escape of HIV from CTL control may also occur by
mechanisms that result in a loss of virus-specific CTL. Sev-
eral potential mechanisms exist, including immune exhaus-
tion (26), loss of virus-specific T helper responses (27, 28),
replicative senescence (29), and apoptosis. Increased rates of
apoptosis in HIV-infected individuals have been widely re-
ported, involving both CD4
 
1
 
 and CD8
 
1
 
 T lymphocytes
(30). Although many pathways may contribute to apoptosis
in HIV infection, interactions between Fas, a member of
the TNF/nerve growth factor receptor superfamily, and
Fas ligand (FasL) appear to play a major role in HIV disease.
In this issue of the 
 
Journal of Experimental Medicine
 
, Xu et al.
(31) now propose that upregulation of FasL by the SIV nef
protein may lead to the loss of virus-specific CTL. The
starting point for these observations was an analysis of CTL
responses in cynomolgus macaques infected with an atten-
uated strain (pC8) of SIV which expresses a defective 
 
nef
 
gene. SIV strains defective in 
 
nef
 
 are inhibited in their abil-
ity to replicate in vivo and cause AIDS (32). Immunization
of animals infected with 
 
nef
 
-deficient SIV strains has pro-
duced the most impressive results against infection with
pathogenic SIV strains (33), an observation that has led to
intensive efforts to define the immune responses that may
be involved in mediating protection. Noting that pC8-
infected animals maintained high levels of virus-specific
CTL responses, while macaques infected with the patho-
genic pJ5 strain have little or no CTL responses, Xu et al.
went on to compare Fas expression and apoptosis in ani-
mals infected with pC8 and pJ5. Animals infected with the
pathogenic pJ5 strain had increased expression of Fas on
both CD4 and CD8 cells, a finding consistent with obser-
vations in HIV-infected people (34). Infection of CD4
 
1
 
 T
cells with the pathogenic strain pJ5 resulted in greater in-
crease in FasL expression than observed in pC8-infected
cells.
These findings are consistent with prior reports that HIV
infection results in upregulation of FasL on infected T cells
and macrophages (35, 36). Upregulation of FasL by Nef on
the surface of HIV- or SIV-infected cells might therefore
serve as a means to induce a local sanctuary from CTL sur-
veillance. Expression of FasL functions in several different
settings to evade or suppress cellular immune responses.
Expression of FasL on Sertoli cells in the testis or on stro-
mal cells of the anterior chamber of the eye appears to ac-
count for the privileged nature of these sites and results in
the death of activated T cells expressing Fas when they en-
ter these sites (37, 38). Similarly, expression of FasL on tu-
mor cells may serve to kill activated lymphocytes and facili-
tate evasion of tumor-specific cellular immune responses (39).
Several caveats should be considered in interpreting these
results. First, clarification of the molecular mechanisms in-
volved in upregulation of FasL is necessary. Using the SIV
strain pC8, which is not deleted in 
 
nef
 
 but expresses a mu-
tant Nef protein, to dissect out the role that 
 
nef
 
 plays in up-
regulation of FasL may be complicated, as variation in the
levels of SIV infection may affect the observed results and
the effect of 
 
nef
 
 may be altered instead of abrogated. Ex-
pression of FasL may be upregulated after activation of T
cells by several routes (40), and it is possible that Nef en-
hances FasL expression mediated by another viral protein
(e.g., Tat) but does not directly upregulate FasL expression.
This latter possibility is suggested by the failure of a recom-
binant vaccinia virus-expressing 
 
nef
 
 to upregulate FasL and
the fact that even the 
 
nef
 
-defective virus pC8 appears to par-
tially upregulate FasL expression (31). HIV Tat has been
shown to upregulate FasL expression independent of Nef
(41). Second, generalization of these results to AIDS patho-
genesis should be carried out with caution. The almost
complete lack of SIV-specific CTL three months after in-
fection with the SIV J5 strain differs with other reports of
SIV-specific CTL in animals infected with pathogenic
strains (42, 43) and clearly contrasts with the generally vig-
orous CTL responses observed in HIV-infected people (3). If
HIV rapidly induced FasL expression on infected cells in
vivo, one might expect a general lack of CTL responses
rather that the observed pattern of persistent but only par-
tially effective CTL. Infection of mice with a recombinant
vaccinia virus expressing FasL does not lead to death of re-
sponding T cells, suggesting that expression of FasL is not
sufficient to induce cell death in vivo (44) and that the fac-
tors affecting the ability of FasL to mediate immune eva-
sion in vivo may be complex.
If confirmed, the implications of these findings for AIDS
pathogenesis are multiple. First, they provide additional ev-
idence supporting the importance of indirect mechanisms
of lymphocyte death induced by HIV or SIV. Observations
that the number of dying T cells far exceeds the number of
 
Table 1.
 
Proposed Mechanisms Employed by HIV-1 to Evade 
Cytotoxic T Lymphocyte Responses
 
Sequence variation
Lack of recognition
Antagonism
Variation in flanking residues
Altered antigen presentation
Downregulation of MHC class I molecules by Tat, Nef
Loss of effector cells
Clonal exhaustion
Loss of CD4 T cell help
Replicative senescence
Fas/Fas ligand–induced apoptosis
Latency
Privileged sites of viral replication 
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HIV or SIV-infected cells have suggested that indirect mech-
anisms, rather than direct virus-induced cytopathic effect,
play a major role in inducing cell death in vivo (45), a con-
clusion bolstered by recent calculations that the percentage
of actively infected CD4
 
1
 
 T cells is rather small (less than
0.02%) (46). Since Fas expression is increased in both
CD4
 
1
 
 and CD8
 
1
 
 T lymphocytes in HIV-infected subjects
(34), FasL-mediated lymphocyte death would increase turn-
over of both T cell subsets. Recent measurements showing
a decrease in telomere length in HIV-infected subjects sup-
port an increased turnover of CD8
 
1
 
 T cells, a finding not
previously anticipated. Second, this report adds to the ex-
panding functions attributed to nef. Originally thought to
function as a downregulator of HIV replication, 
 
nef
 
 is in fact
necessary for efficient in vivo replication for both SIV and
HIV (32, 47), although the molecular mechanism underly-
ing this positive effect has proved elusive. Specific functions
ascribed to 
 
nef
 
 based on in vitro experiments include down-
regulation of CD4 expression (48), downregulation of MHC
class I expression (24), enhancement of virion infectivity
(49), and activation of lymphocytes (50). With the addition
of upregulation of FasL to this list, dissecting out which of
these in vitro functions is responsible for the in vivo effect
of 
 
nef
 
 represents an important goal. Finally, this report of-
fers an alternative approach for AIDS therapy directed at
interfering with the Fas–FasL interactions either by drugs
that affect Fas-induced cell death (35) or by soluble Fas
protein.
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